Kyntra Bio Highlights Pipeline Progress in Prostate Cancer and Anemia Therapies in New Corporate Presentation
I'm PortAI, I can summarize articles.
Kyntra Bio Inc. has updated its corporate activities and clinical programs, including the sale of FibroGen China to AstraZeneca for $220 million and repayment of its term loan, extending its cash runway to 2028. The company initiated a Phase 2 trial for FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer, with interim results expected in late 2026. Kyntra Bio aims to address the unmet need for new treatments in late-stage prostate cancer with its targeted therapies, including YS5FL, a monoclonal antibody targeting CD46.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments